Sample size requirements in trials using repeated measurements and the impact of trial design

Current Medical Research and Opinion

Volumn 28, Issue 5, 2012, Pages 681-688

  Peters, Sanne A E ^a   Palmer, Mike K ^b   Den Ruijter, Hester M ^a   Grobbee, Diederick E ^a   Crouse Iii, John R ^c   O'Leary, Daniel H ^d   Evans, Gregory W ^c   Raichlen, Joel S ^e   Bots, Michiel L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b KEELE UNIVERSITY   (United Kingdom)

^c WAKE FOREST SCHOOL OF MEDICINE   (United States)

^d Carney Hospital   (United States)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Carotid intima media thickness; Repeated measures; Sample size; Trial design

Indexed keywords

PLACEBO; ROSUVASTATIN;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR SYSTEM EXAMINATION; CLINICAL TRIAL; CONTROLLED STUDY; COST; DRUG EFFECT; DRUG EFFICACY; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; PATIENT ASSESSMENT; SAMPLE SIZE; TREATMENT DURATION; TREATMENT OUTCOME; VARIANCE;

CAROTID ARTERIES; CAROTID ARTERY DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CLINICAL TRIALS AS TOPIC; FEMALE; FLUOROBENZENES; FOLLOW-UP STUDIES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SAMPLE SIZE; SULFONAMIDES; TIME FACTORS;

EID: 84861126167     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007995.2012.678937     Document Type: Article

References (24)

1. Sullivan LM. Repeated measures. Circulation 2008;117:1238-43 (Pubitemid 351544057)
2. Schlesselman JJ. Planning a longitudinal study. I. Sample size determination. J Chronic Dis 1973;26:553-60
3. Schlesselman JJ. Planning a longitudinal study. II. Frequency of measurement and study duration. J Chronic Dis 1973;26:561-70
4. Fitzmaurice G, Laird N, Ware J. Applied Longitudinal Analysis. Hoboken, NJ, USA: Wiley & Sons, 2004
5. Crouse III JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. JAMA 2007;297:1344-53 (Pubitemid 46513235)
6. Crouse III JR, Grobbee DE, O'Leary DH, et al. Measuring Effects on intima media Thickness: an Evaluation Of Rosuvastatin in subclinical atherosclerosis -the rationale and methodology of the METEOR study. Cardiovasc Drugs Ther 2004;18:231-8 (Pubitemid 38918958)
7. Bots ML, Hoes AW, Koudstaal PJ, et al. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-7 (Pubitemid 27375333)
8. O'Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22 (Pubitemid 29024679)
9. Espeland MA, O'Leary DH, Terry JG, et al. Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med 2005;6:3
10. Wang JG, Staessen JA, Li Y, et al. Carotid intima-media thickness and antihypertensive treatment: a meta-analysis of randomized controlled trials. Stroke 2006;37:1933-40 (Pubitemid 44297754)
11. Espeland MA, Craven TE, Riley WA, et al. Reliability of longitudinal ultrasonographic measurements of carotid intimal-medial thicknesses. Asymptomatic Carotid Artery Progression Study Research Group. Stroke 1996;27:480-5 (Pubitemid 26081446)
12. Furberg CD, Adams Jr HP, Applegate WB, et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-87 (Pubitemid 24320914)
13. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-25 (Pubitemid 32183795)
14. Mercuri M, Bond MG, Sirtori CR, et al. Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med 1996;101:627-34 (Pubitemid 27150041)
15. Pitt B, Byington RP, Furberg CD, et al. Effect of amlodipine on the progression of atherosclerosis and the occurrence of clinical events. PREVENT Investigators. Circulation 2000;102:1503-10
16. Smilde TJ, van WS, Wollersheim H, et al. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001;357:577-81 (Pubitemid 32179609)
17. Overall JE, Doyle SR. Estimating sample sizes for repeated measurement designs. Control Clin Trials 1994;15:100-23 (Pubitemid 24236473)
18. Dupont WD, Plummer Jr WD. Power and sample size calculations for studies involving linear regression. Control Clin Trials 1998;19:589-601 (Pubitemid 29057724)
19. Peters SA, Palmer MK, Grobbee DE, et al. Effect of number of ultrasound examinations on the assessment of carotid intima-media thickness changes over time: the example of the METEOR study. J Hypertens 2011;29:1145-54
20. White IR, Horton NJ, Carpenter J, et al. Strategy for intention to treat analysis in randomised trials with missing outcome data. BMJ 2011;342:d40
21. Bots ML, Palmer MK, Dogan S, et al. Intensive lipid lowering may reduce progression of carotid atherosclerosis within 12 months of treatment: the METEOR study. J Intern Med 2009;265:698-707
22. Bots ML, Visseren FL, Evans GW, et al. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, doubleblind trial. Lancet 2007;370:153-60 (Pubitemid 47042895)
23. Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008;358:1431-43 (Pubitemid 351482735)
24. Kastelein JJ, van Leuven SI, Burgess L, et al. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia. N Engl J Med 2007;356:1620-30 (Pubitemid 46631671)